首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Agreement of Immunosuppression Regimens Described in Medicare Pharmacy Claims with the Organ Procurement and Transplantation Network Survey
【24h】

Agreement of Immunosuppression Regimens Described in Medicare Pharmacy Claims with the Organ Procurement and Transplantation Network Survey

机译:Medicare药房索赔中描述的免疫抑制方案与器官采购和移植网络调查的协议

获取原文
获取外文期刊封面目录资料

摘要

The Organ Procurement and Transplantation Network (OPTN) collects intermittent survey data on immunosuppressive medication use that are studied frequently as research measures. Pharmacy billing claims may provide an accurate measure of immunosuppression use over time. Herein is characterized the agreement of Medicare pharmacy claims for immunosuppressive medications with OPTN reports. Data were drawn from the United States Renal Data System. Participants received a kidney transplant in 2000 to 2001 and had an OPTN record and a Medicare pharmacy claim for an immunosuppressive drug at transplant discharge and 6 mo and 1 yr after transplantation. The concordance (?o) of the OPTN and claims (?±30 d of survey) for indicated medication use was compared, and sensitivity, specificity, and predictive values for claims were computed, assuming OPTN as a a€?gold standard.a€? Clinical trial participation and regimen changes were examined as explanations for discordance. A total of 4357 eligible subjects were identified. Concordance over observation ranged from excellent for calcineurin inhibitors (?o 0.86) to generally very good for adjunctive agents (?o = 0.49 to 0.75) to poor for corticosteroids (?o 0.15). Claims demonstrated high positive predictive values (a‰¥97%) but low negative predictive values (a‰¤13%) for OPTN-reported corticosteroid use. Regimen changes (28 to 75%) but not clinical trial participation (a‰¤21%) were identified frequently among cases with discordant indications of nonsteroid medication use. Close agreement of Medicare billing claims and the OPTN for indicated use of nonsteroid immunosuppressive medications supports both as useful measures of drug exposure. Low detection rates of OPTN-indicated corticosteroid use within claims require further examination.
机译:器官采购和移植网络(OPTN)收集有关免疫抑制药物使用的间歇性调查数据,这些数据经常作为研究手段进行研究。药房帐单声明可以提供随时间推移免疫抑制使用的准确度量。本文的特征是带有OPTN报告的Medicare药房权利要求书中关于免疫抑制药物的协议。数据来自美国肾脏数据系统。参与者于2000年至2001年接受了肾脏移植,并有OPTN记录,并在Medicare药房要求在移植后以及移植后6 mo和1年使用免疫抑制药物。假设OPTN为金标准,比较OPTN与声明用药的声明(调查的±30 d)的一致性(?o),并计算声明的敏感性,特异性和预测值。 ?检查了临床试验的参与程度和方案变更,以作为不一致的解释。总共确定了4357名合格受试者。观察结果的一致性范围从钙调神经磷酸酶抑制剂的极好(Δo> 0.86)到一般的辅助剂非常好(Δo= 0.49至0.75)到皮质类固醇的差(Δo<0.15)。声称对OPTN报告的皮质类固醇激素的使用具有较高的阳性预测值(≥97%),而较低的阴性预测值(≥13%)。在非甾体药物使用的适应症不同的病例中,经常发现方案变化(28%至75%),但没有临床试验参与(21%)。 Medicare帐单声明和OPTN明确同意使用非类固醇免疫抑制药物,这两者均是药物暴露的有用衡量指标。要求范围内OPTN指示的糖皮质激素使用率低,需要进一步检查。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号